Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.27
|
1.55
|
1.30
|
1.26
|
1.396
|
1.30
|
|
|
33 067.96
|
194.00
|
1.22
|
1.55
|
1.35
|
1.345
|
1.42
|
1.36
|
|
|
39 854.19
|
220.00
|
1.26
|
1.39
|
1.30
|
1.25
|
1.34
|
1.29
|
|
|
26 245.14
|
182.00
|
0.90
|
1.39
|
1.30
|
1.21
|
1.36
|
1.26
|
|
|
58 546.86
|
262.00
|
1.16
|
1.39
|
1.32
|
1.26
|
1.40
|
1.33
|
|
|
60 295.44
|
254.00
|
1.23
|
1.39
|
1.15
|
1.1345
|
1.34
|
1.32
|
|
|
64 703.09
|
284.00
|
1.00
|
1.40
|
1.15
|
1.0708
|
1.195
|
1.16
|
|
|
10 639.76
|
196.00
|
1.04
|
1.40
|
1.18
|
1.17
|
1.31
|
1.18
|
|
|
37 139.37
|
186.00
|
1.11
|
1.22
|
1.03
|
1.03
|
1.2283
|
1.20
|
|
|
54 307.34
|
289.00
|
1.00
|
1.64
|
1.19
|
0.98
|
1.19
|
1.09
|
|
|
40 836.96
|
372.00
|
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR.